Dicarboxylic acids and derivatives
Selleck Chemical LLC (R)-(-)-Gossypol (AT-101) acetic acid S2812-10mM/1mL
(R)-(-)-Gossypol (AT-101) acetic acid the R-(-) enantiomer of Gossypol acetic acid binds with Bcl-2 Bcl-xL and Mcl-1 with Ki of 0 32 M 0 48 M and 0 18 M in cell-free assays does not inhibit BIR3 domain and BID AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy Phase 2
Selleck Chemical LLC (R)-(-)-Gossypol (AT-101) acetic acid S2812-1g
(R)-(-)-Gossypol (AT-101) acetic acid the R-(-) enantiomer of Gossypol acetic acid binds with Bcl-2 Bcl-xL and Mcl-1 with Ki of 0 32 M 0 48 M and 0 18 M in cell-free assays does not inhibit BIR3 domain and BID AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy Phase 2
![Medchemexpress LLC 3-cyclopropyl-1-[[4-[6-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]-5-fluoropyridin-2-yl]phenyl]methyl]imi | 2250025-91-1 | Not found | 99.4% | 508.99 | C23H25FN4O4S·HCl | 25MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000236923.png-250.jpg)
Medchemexpress LLC 3-cyclopropyl-1-[[4-[6-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]-5-fluoropyridin-2-yl]phenyl]methyl]imi | 2250025-91-1 | Not found | 99.4% | 508.99 | C23H25FN4O4S·HCl | 25MG
LEI-101 hydrochloride is a potent, selective, orally bioavailable cannabinoid CB2 receptor agonist supplied for research use. It demonstrates strong functional activity at human CB2 receptors with substantially lower affinity for CB1 and minimal hERG binding, suitable for in vitro and in vivo pharmacology studies.
- Purity 99.4%.
- Reported activity pEC50 = 8 for human CB2.
- Approximately 100-fold selectivity for CB2 over CB1.
- Low hERG interaction (pKi < 4).
- Soluble in DMSO; available as dry powder and 10 mM solution in DMSO.
- Intended for research use only; not for human or clinical use.
Medchemexpress LLC Ji-101 | 900573-88-8 | MFCD26142530 | 99.8% | 466.33 | C22H20BrN5O2 | 10 MG
JI-101 is an orally available multi-kinase inhibitor that targets VEGFR2, PDGFRβ, and EphB4 and has demonstrated potent anti-cancer activity. It is provided as a white to off-white solid powder for research use and is commonly supplied in a 10 mg pack.
- Orally available multi-kinase inhibitor active against VEGFR2, PDGFRβ, and EphB4.
- High purity (99.78%).
- Molecular formula C22H20BrN5O2; molecular weight 466.33 g/mol.
- White to off-white solid, soluble in DMSO at ≥ 100 mg/mL.
- Intended for research use only; not for human administration.
TARGETMOL CHEMICALS INC PKUMDL-LC-101-D04 5MG
Also available in 1 mg 10 mg 25 mg 50 mg 100 mg 500 mg and bulk. Please contact Fisher for quotes. PKUMDL-LC-101-D04 is a potent allosteric activator of glutathione peroxidase 4 (GPX4) a regulator of iron death. GPX4 activity was increased to 150% of control levels when used at a concentration of 20 uM in a cell-free assay and at a concentration of 61 uM in wild-type but not Gpx4-/- mouse embryonic fibroblast (MEF) extracts.PKUMDL-LC-101-D04 (200 uM) reduced cholesterol peroxide-induced MEF death. purity: 98%
Apexbio Technology LLC LOXO-101 1223405-08-0 25mg
LOXO-101 (CAS 1223405-08-0) is a potent and selective inhibitor of the tropomyosin receptor kinase (TRK) family demonstrating low nanomolar inhibitory activity across all TRK isoforms LOXO-101 disrupts signaling mediated by neurotrophin receptors which are critical for neuronal development and survival In kinase profiling LOXO-101 exhibited minimal off-target activity with significant inhibition observed only for TNK2 (IC50 576 nM) and did not display hERG inhibition or QT prolongation effects In vivo studies revealed dose-dependent tumor growth suppression in xenograft models Clinically LOXO-101 has been evaluated for safety and pharmacokinetics and induced rapid tumor regression in a TRK fusion-positive patient highlighting its utility in studying TRK-driven malignancies
